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ORIGINAL ARTICLE
Nasal high ﬂow therapy and PtCO2 in stable COPD: A randomized
controlled cross-over trial
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ABSTRACT
Background and objective: Hypercapnia is associated
with worse clinical outcomes in exacerbations of COPD.
The present study aimed to determine the effects of nasal
high ﬂow (NHF) therapy on transcutaneous partial pres-
sure of carbon dioxide (PtCO2) in stable COPD patients.
Methods: In a single-blind randomized controlled cross-
over trial, 48 participants with COPD were allocated in
random order to all of four 20 min interventions: NHF at
15 L/min, 30 L/min and 45 L/min or breathing room air
with each intervention followed by a washout period of
15 min. The primary outcome measure was PtCO2 at
20 min, adjusted for baseline PtCO2. Secondary outcomes
included respiratory rate at 20 min, adjusted for baseline.
Results: The mean (95% CI) change in PtCO2 at 20 min
was −0.6 mm Hg (−1.1 to 0.0), P = 0.06; −1.3 mm Hg
(−1.9 to 0.8), P < 0.001; and −2.4 mm Hg (−2.9 to −1.8),
P < 0.001; for NHF at 15 L/min, 30 L/min and 45 L/min
compared with room air, respectively. The mean (95%
CI) change in respiratory rate at 20 min was −1.5 (−2.7
to −0.3), P = 0.02; −4.1 (−5.3 to −2.9), P < 0.001; and
−4.3 (−5.5 to −3.1), P < 0.001; breaths per minute com-
pared with room air, respectively.
Conclusion: NHF results in a small ﬂow-dependent
reduction in PtCO2 and respiratory rate in patients with
stable COPD.
Clinical trial registration: ACTRN12615000471583 at anzctr.
org.au
Key words: arterial partial pressure, carbon dioxide, chronic
obstructive respiratory disease, nasal high ﬂow, randomized
controlled trial.
Abbreviations: FEV1, forced expiratory volume in 1 s; FVC,
forced vital capacity; NHF, nasal high ﬂow; NIV, non-invasive
ventilation; PaCO2, partial pressure of arterial carbon dioxide;
PtCO2, transcutaneous partial pressure of carbon dioxide; RIP,
Respiratory Inductance Plethysmography; StO2, transcutaneous
oxygen saturation.
INTRODUCTION
In acute exacerbations of COPD, hypercapnia is associ-
ated with worse clinical outcomes including death.1 Non-
invasive ventilation (NIV) is recommended to provide
respiratory support to patients with exacerbations of
COPD who have hypercapnic respiratory failure despite
optimal medical therapy.2 Tolerability of NIV may be a
barrier to effective use3 and an alternative to NIV is a prior-
ity for themanagement of acute exacerbations of COPD.
Nasal high ﬂow (NHF) therapy may cause a modest
reduction in the partial pressure of arterial carbon diox-
ide (PaCO2) in both stable and acute COPD.
4–9 How-
ever, the interpretation of studies of NHF, and their
applicability to clinical practice, remains variably limited
by the confounding effect of concomitant oxygen ther-
apy, absence of randomized controlled treatments and
a lack of data on the dose–response relationship across
the range of ﬂows used in clinical practice.
The present study is a randomized controlled cross-
over trial of the effect of three different ﬂow rates of
NHF therapy compared with a control intervention of
room air, in patients with stable COPD who do not
need concomitant oxygen therapy. The main objective
of the present study was to determine the ﬂow-
response relationship of NHF therapy and PaCO2 in
stable COPD. The hypothesis was that NHF therapy
would cause a ﬂow-dependent reduction in PaCO2 and
respiratory rate in stable COPD.
METHODS
In this single-blind, randomized, controlled, four-way
cross-over trial, 48 participants with a doctor’s diagno-
sis of COPD, aged at least 40 years and with a tobacco
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SUMMARY AT A GLANCE
In patients with stable COPD, the administration of
nasal high ﬂow results in ﬂow-dependent reduc-
tions in transcutaneous partial pressure of carbon
dioxide and respiratory rate.
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smoking history of ≥10 pack years were recruited. Par-
ticipants were excluded if their forced expiratory vol-
ume in 1 s (FEV1)/ forced vital capacity ratio was >0.7,
or if they were on long-term oxygen therapy, had a cur-
rent exacerbation of COPD requiring a short course of
antibiotics or oral glucocorticoids or oxygen therapy, or
hospitalization for an acute exacerbation of COPD
within the last 6 weeks. People with nasal conditions
potentially affecting the ability to use NHF were also
excluded. Eligible participants attended a single study
visit at the MRINZ Respiratory Physiology Laboratory at
Wellington Regional Hospital.
The present study was prospectively registered with
ANZCTR (Trial ID: ACTRN12615000471583) and
approved by the Health and Disability Ethics Commit-
tee of New Zealand (Ref: 15/NTA/4). Full written
informed consent was completed before any study-
speciﬁc procedures.
After demographic data was collected, spirometry
was performed in accordance with American Thoracic
Society/European Respiratory Society criteria10 using a
Jaeger Master screen body volume constant plethys-
mography unit with pneumotachograph and diffusion
unit (Erich-Jaegar, Wurzburg, Germany). Measure-
ments of transcutaneous partial pressure of carbon
dioxide (PtCO2), transcutaneous oxygen saturation
(StO2) and heart rate were made using the SenTec
transcutaneous monitor (SenTec digital monitor with
V-Sign Sensor VS-A/P/N, Therwil, Switzerland; further
details in the Appendix S1 in Supplementary Informa-
tion). The SenTec probe was kept on the patient for
between 20 and 30 min before the subsequent study
procedures to ensure a stable baseline measurement of
PtCO2.
Minute ventilation was measured using Respiratory
Inductance Plethysmography (RIP) bands (QDC-Pro
device; CareFusion, Yorba Linda, California, USA). Fur-
ther details are given in the Appendix S1 in Supple-
mentary Information.
Participants received all interventions for 20 min in a
randomized order while seated. Each NHF ﬂow setting
was at a temperature of 37C without oxygen: 15 L/
min, 30 L/min or 45 L/min; or the control setting of
breathing room air only without the NHF attached,
using the myAIRVO 2 device (PT101AZ; Fisher and
Paykel Healthcare, Auckland, New Zealand). Further
details are given in the Appendix S1 in Supplementary
Information.
Each of the four interventions was followed by a
washout period breathing room air for at least 15 min,
allowing the PtCO2 to return to within 4 mm Hg of the
baseline measurement for the particular intervention.
The washout could be extended until this criterion
was met.
PtCO2, StO2, heart rate and respiratory rate were
recorded at the start of each intervention and then
every 5 min until the end of each washout period.
The order of administration of the four treatments
was randomized. The randomisation was computer-
generated by the study statistician, who had no role
in the recruitment, study visits or data collection.
Treatment allocation and maintenance of blinding
are described in the Appendix S1 in Supplementary
Information.
Participant tolerability questionnaires were adminis-
tered during the washout periods after each NHF inter-
vention. Participants rated the ease of application, level
of comfort, weight of the nasal interface, noisiness,
amount of moisture in the nasal passages and likeli-
hood of reusing the system on a continuous scale from
most positive (0) to least positive (100).
Outcomes
The primary outcome was PtCO2 at 20 min, adjusted
for baseline PtCO2. Secondary outcomes were: the pro-
portion of participants who had a decrease in PtCO2 ≥
4 mm Hg from baseline during the intervention; PtCO2,
respiratory rate, StO2, heart rate and minute ventilation
adjusted for baseline for each 5-min time-point during
the intervention and the subsequent 15 min washout
period; the proportion of participants who withdrew
from the intervention before it was completed; and
results of the tolerability questionnaires.
Statistical analysis
The paired SDs of PtCO2 in a previous study investigat-
ing oxygen administration to patients with stable COPD
were between 1.8 and 4.4 mm Hg.11 Based on the high-
est PtCO2 SD of 4.4 mm Hg, and an alpha value of
0.0083 (to take into account the potential for six possi-
ble comparisons for the four-way cross-over study) a
sample size of 48 had 90% power to detect a difference
in PtCO2 of 3.8 mm Hg.
The comparison of each of the three NHF treatments
compared to room air was by mixed linear model with
ﬁxed effects for the randomisation sequence, the base-
line measurement of the particular variable, and the
randomized treatment, time and their interaction; and
a random effect for each participant, with an exponen-
tial time correlation structure for the repeated mea-
surements. The comparison of paired proportions for
those that had a decrease from baseline PtCO2 of
≥4 mm Hg was by an exact McNemar’s test and esti-
mation of the CI for the differences in paired propor-
tions, NHF intervention minus room air, by an
asymptotic method. The comparison of device ques-
tionnaire scores was by a mixed linear model with ﬁxed
effects for the randomization sequence and treatment;
and a random effect for the participant. In a post hoc
analysis, the statistical test of whether the PtCO2
response to treatment differed by whether the baseline
PtCO2 was >45 mm Hg or not was the interaction
P value. The above-mentioned analysis was carried out




Contact was made with 84 potentially eligible partici-
pants of whom 48 were randomized between May 2015
and February 2016 (Fig. 1).
Three participants required an extended washout in
at least one of the interventions past the planned
15 min washout for the PtCO2 to return to within 4 mm
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Hg of the time point zero reading, with the longest
extension being 10 min.
Participant characteristics are shown in Table 1.
Twenty-nine of the participants were male and 6/48
(12.5%) were hypercapnic, with PtCO2 > 45 mm Hg, at
randomization. Twenty-four participants (50%) had
severe or very severe COPD according to the Global
Initiative for Chronic Obstructive Lung Disease (GOLD)
classiﬁcation.12
Transcutaneous partial pressure of carbon
dioxide
The mean PtCO2 adjusted for baseline after 20 min
compared to room air was lower for NHF with a ﬂow-
dependent reduction in PtCO2 (Table 2). The mean dif-
ference in PtCO2 compared to room air was −2.4 mm
Hg (95% CI: −2.9 to −1.8), P < 0.001, −1.3 mm Hg (95%
CI: −1.9 to −0.8), P < 0.001 and −0.6 mm Hg (95% CI:
−1.1 to 0.0), P = 0.06 for NHF at 45 L/min, 30 L/min
and 15 L/min, respectively. There was no signiﬁcant
interaction between treatment response and whether
the baseline PtCO2 was greater than 45 mm Hg or
not, P = 0.74.
The proportion of participants with at least one mea-
surement of PtCO2 which decreased from baseline
≥4 mm Hg, up to and including the 20-min treatment
period was 15/48 (31.2%), 8/48 (16.7%) and 2/48
(4.2%) for NHF at 45 L/min, 30 L/min and 15 L/min,
respectively, and 1/48 (2.1%) for room air. The paired
proportions difference for NHF minus room air was
29.7% (95% CI: 16.3–42.0), P < 0.001, 14.6% (95% CI:
4.6–24.6), P = 0.016 and 2.1% (95% CI: −2.0 to 6.1),
P = 0.99, for NHF at 45 L/min, 30 L/min and 15 L/min,
respectively. Four participants (8.3%) had at least one
measurement of PtCO2 which decreased from baseline
≥8 mm Hg, up to and including the 20-min treatment
period for NHF at 45 L/min.
Respiratory rate
There were signiﬁcant reductions in respiratory rate
between NHF compared to room air at 20 min with a
ﬂow rate dependent effect (Table 3). The maximum point
estimate difference in respiratory rate was −5.0 breaths
per minute (95% CI: −6.2 to −3.8), P < 0.001, at 5 min
with NHF at 45 L/min compared to room air, represent-
ing a 28% reduction from the baseline respiratory rate.
Oxygen saturation and heart rate
The StO2 was higher for NHF 45 L/min compared
to room air at the 5, 15 and 20 min time points.
The mean maximum difference in StO2 was 0.8%
(95% CI: 0.41–1.28), P < 0.001, observed after 5 min for
NHF 45 L/min compared to room air (Table S1
(Supplementary Information)).
Heart rate remained largely constant throughout the
interventions with no statistically signiﬁcant differences
between any of the NHF interventions and room air,
with the exception of the 20-min time point for the
15 L/min where it was 2 beats per minute higher (95%
CI: 0.25–3.8), P = 0.025 (Table S2 (Supplementary
Information)).
The full-set of mean data for each variable is shown
in the Tables S3–S6 in Supplementary Information.
Minute ventilation
In 97/192 (51%) interventions, the RIP measurements
were valid, and of the 144 planned comparisons
between NHF and room air, in only 52 (36%) were both
NHF and room air measurements valid. For this rea-
son, the RIP data is not presented.
Tolerability questionnaires
Participant feedback was that NHF at 45 L/min was
less comfortable and noisier, but moister than NHF at
15 L/min (Table 4). NHF at 30 L/min was generally
more tolerable than 45 L/min.
DISCUSSION
The NHF device resulted in a small ﬂow-dependent
reduction in the PtCO2 in participants with stable
COPD. There was a marked ﬂow-dependent reduction
in respiratory rate with the use of NHF. These ﬁndings
suggest a favourable physiological effect with NHF in
stable COPD.
There are a number of methodological issues rele-
vant to the interpretation of the study ﬁndings. Our
study was single-blinded in that although participants
were blinded to the actual ﬂow rate they received, they
could feel the difference between low, medium and
high ﬂows. The interventions were applied for 20 min
periods, which was sufﬁcient time to observe an effect
on PtCO2 with the maximum change usually observed
at the 5-min time point. There was a washout period
Screening phone call and/or PIS sent 
to potentially eligible participants on 
MRINZ database (n = 84)
Excluded (n = 36)
- Not meeting inclusion criteria 
(n = 5)
 On LTOT (n = 1)
 Current exacerbation 
(n = 3)
 No COPD (n = 1)
- No further contact (n = 14) 
- Declined (n = 12)
- Unsuitable, other reasons 
(n = 5)
Randomized (n = 48) to 4 interventions: 
NHF 15 L/min 
NHF 30 L/min 
NHF 45 L/min 
Room air 
Completed all 4 interventions 
(n = 48) 
Analysis completed (n = 48) 
RIP data not analysed 
Figure 1 Participant ﬂow through the study and allocation of
interventions. LTOT, long-term oxygen therapy; NHF, nasal high
ﬂow; PIS, participant information sheet; RIP, Respiratory Induc-
tance Plethysmography.
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which allowed each of the four intervention periods to
begin within a similar baseline PtCO2.
The external validity of the ﬁndings was limited in
the respect that participants with stable COPD were
recruited, rather than during a severe exacerbation, in
which NHF is more likely to be administered. However,
this design enhanced the internal validity, allowing a
cross-over design to be utilized with a single study visit,
which importantly enabled a stable baseline PtCO2 to
be achieved before each intervention. It also avoided
the confounding effect of supplemental oxygen use, a
potential limiting factor in previous studies of NHF
therapy in exacerbations of COPD, in which lower
inspired concentrations of oxygen with NHF may have
contributed to the reductions in PaCO2 observed.
4–6
There was a broad cross-section of severity of COPD,
with one in eight having hypercapnia and one in two
having an FEV1 < 50% predicted. A post hoc analysis
showed no evidence that the change in PtCO2 in
response to treatment varied by whether the patient
was in chronic hypercapnic respiratory failure.
The transcutaneous SenTec monitor has been vali-
dated and used as a surrogate measure of PaCO2,
allowing continuous monitoring and the avoidance of
multiple arterial blood gas punctures.13–17 The RIP
measures were not valid for most interventions and so
it was not possible to directly measure the effect of
NHF on minute ventilation or tidal volume.
Our observations showed that NHF reduces PtCO2 in
a ﬂow-dependent manner complements previous work.
The small reduction in PtCO2 of 2.4 mm Hg at 45 L/
min is similar to the 3.4 mm Hg reduction with NHF at
30 L/min for 20 min in COPD patients on long-term
oxygen therapy,4 the 3.1 mm Hg reduction with NHF at
20 L/min for 45 min in COPD patients requiring sup-
plemental oxygen at 2 L/min in hospital,6 and the
reduction of 1.4 mm Hg observed in our previous
study of patients hospitalized with exacerbations of
COPD, where supplemental oxygen delivered with
NHF was titrated to maintain patient StO2 at hospital
pre-study levels.7 However, it is less than the 5.2 mm
Hg and 7.3 mm Hg reduction in PtCO2 observed with
2 h of NHF treatment, at 20 L/min and 30 L/min
respectively, in the uncontrolled trial of hospitalized
COPD patients8 and the non-signiﬁcant 4.0 mm Hg
and 5.5 mm Hg reduction in PaCO2 in COPD patients
with chronic hypercapnic respiratory failure receiving
NHF therapy for 30 min at 20 L/min and 30 L/min,
respectively.9 While the mean reduction in PtCO2 of
2.4 mm Hg found in our study is of uncertain clinical
Table 1 Baseline participant characteristics
Characteristic n = 48 for all Mean (SD) Median (IQR) Min to max
Age (years) 69.4 (8.6) 70 (62–74) 52–87
BMI (kg/m2) 27.6 (6.7) 25.7 (53.4–30.3) 14.5–48.4
FEV1 (L) 1.55 (0.64) 1.44 (1.03–1.87) 0.50–3.0
FEV1/FVC (%) 47.2 (11.5) 47.5 (36.2–55.1) 28.4–66.9
FEV1% predicted 52.5 (19.6) 49.6 (37.2–68.2) 18.5–88.6
FVC (L) 3.24 (0.88) 3.10 (2.58–3.90) 1.63–5.41
Smoking pack years 46.1 (31.2) 41.5 (30.0–58.0) 13.0–200.0
MMRC 1.17 (0.31) 1 (0–2) 0–3
PtCO2 (mm Hg) 37.8 (6.1) 36.7 (33.8–39.6) 28.8–55.8
StO2 (%) 94.9 (2.4) 95.0 (94.1–97.0) 88–99
Respiratory rate (breaths per minute) 17.8 (5.5) 16.5 (14.0–21.5) 7.0–30.0
Heart rate (beats per minute 74.6 (14.1) 74.5 (66.6–81.0) 48.0–118
n/48 (%)











Inhaled corticosteroid 34 (70.8)
Long-acting beta-agonist 34 (70.8)
Long-acting muscarinic antagonist 19 (40.0)
Short-acting beta-agonist 34 (70.8)
Short-acting muscarinic antagonist 15 (31.3)
FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; IQR, interquartile range; MMRC, Modiﬁed Medical Research Coun-
cil; PtCO2, transcutaneous carbon dioxide, StO2, transcutaneous oxygen saturation.
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signiﬁcance, the reduction in PtCO2 from baseline of
≥8 mm Hg in 4/48 participants on NHF at 45 L/min
suggests this therapy may have clinically important
effects on PtCO2 in a proportion of patients
with COPD.
The reduction in respiratory rate with NHF we
observed has been reported in healthy volunteers,18 in
COPD patients,4–6,19 and in other clinical situations
such as pulmonary ﬁbrosis and post-cardiac surgical
patients.5,20 The magnitude of the reduction in respira-
tory rate was marked with a maximum 5 breaths per
minute reduction after 5 min of NHF at 45 L/min,
representing a >25% reduction in respiratory rate. It
has recently been reported that in patients with COPD
and chronic hypercapnic respiratory failure that a
reduction in respiratory rate of this magnitude with
NHF therapy is associated with reduced respiratory
muscle load, with a reduction in transdiaphragmatic
pressures and an increase in expiratory time. 9
The ﬂow-dependent physiological effects on PtCO2
and respiratory rate we observed with NHF in COPD
patients was consistent with the observed ﬂow-
dependent increase in airway pressure, end expiratory
pressures, end expiratory lung volume and inspiratory
pressures observed in post-cardiac surgery patients,20,21
and airway pressures in healthy volunteers18 and COPD
patients.8 The modest reduction in PtCO2 indicates
alveolar ventilation was increased despite the marked
reduction in respiratory rate. The relative contributions
of increases in alveolar volume and/or reductions in
physiological dead space to the increase in alveolar
ventilation were not assessed in this study. Other
mechanisms which may play a role but were not
assessed in the study include an increase in tidal vol-
ume, a small positive end-expiratory pressure effect,
reduction in upper airway resistance and improved
mucociliary clearance from humidiﬁcation of the
airways.4,8,22–24
Previous studies have shown improved tolerability of
NHF compared to both face masks and standard nasal
prongs25–27 and it was generally well tolerated in our
study. Given NHF at 30 L/min reduced PtCO2 and
respiratory rate by a similar amount to NHF at 45 L/
min, but was more comfortable, this ﬂow rate may be
preferred in clinical practice.
In conclusion, NHF results in a small reduction in
PtCO2 and a marked reduction in respiratory rate, in a
ﬂow-dependent manner with the higher the ﬂow the
greater the effect. Further studies need to be under-
taken to compare NHF against the gold standard of
NIV in acute exacerbations of COPD associated with
respiratory failure.
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